Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Int Ophthalmol ; 36(2): 237-42, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26260358

ABSTRACT

To compare the cyclosporine 0.05 % exposure effect on fibroblasts from primary and recurrent pterygium. Primary culture of fibroblasts from primary and recurrent pterygium was performed until the third passage, which was exposed to cyclosporine 0.05 % in a group and the other remaining unexposed (control group), in triplicates. After 3, 6, 12, and 17 days of exposure the viable cell counting was performed by hemocytometer. The results were statistically analyzed using the technique of analysis of non-parametric variance model for repeated measures with three factors. There was a significant reduction in both fibroblast proliferation, in primary as in the recurrent pterygium cultures exposed to cyclosporine when compared not exposed cultures, with statistical significance (P < 0.05). Comparing primary and recurrent pterygium that received the drug, there was no significant difference in cell proliferation in relation to primary or recurrent pterygium. Cyclosporine 0.05 % is effective in inhibiting fibroblast proliferation in culture, both in primary and as in recurrent pterygium.


Subject(s)
Cyclosporine/pharmacology , Fibroblasts/drug effects , Immunosuppressive Agents/pharmacology , Pterygium/drug therapy , Analysis of Variance , Cell Count , Cell Proliferation/drug effects , Humans , Prospective Studies
2.
Arq. bras. oftalmol ; 69(6): 831-835, nov.-dez. 2006. graf
Article in Portuguese | LILACS | ID: lil-440420

ABSTRACT

OBJETIVO: Avaliar o comportamento dos fibroblastos da cápsula de Tenon de pterígios e normais em cultura, quando expostos a ciclosporina 0,05 por cento. MÉTODOS: Estudo prospectivo, controlado, do qual participaram 20 portadores de pterígio primário. Foram colhidas amostras da cápsula de Tenon normal e proveniente do pterígio, ambas do mesmo indivíduo, colocadas para crescimento em cultura e expostas a ciclosporina 0,05 por cento. As avaliações foram feitas aos 3, 6, 12 e 17 dias após a exposição. RESULTADOS: Das amostras colhidas, 7 foram utilizadas para exposição a ciclosporina - 6 provenientes de pterígios e 1 da Tenon normal. Houve redução significativa na proliferação celular das culturas de fibroblastos expostos a ciclosporina (p<0,05). CONCLUSÃO: A ciclosporina 0,05 por cento é capaz de inibir a proliferação de fibroblastos provenientes da cápsula de Tenon de pterígio e também da Tenon normal. Novos estudos devem ser providenciados para definir o papel da ciclosporina no tratamento do pterígio.


PURPOSE: To evaluate normal Tenon capsule fibroblasts and from pterygia in culture when exposed to cyclosporin 0.05 percent. METHODS: A prospective, randomized study was done, involving 20 patients with primary pterygium. Samples of normal and pterygium Tenon's capsule from the same individual were collected, cultured and exposed to cyclosporin 0.05 percent. RESULTS: Only 7 samples could be exposed to cyclosporin - 6 from pterygial Tenon's capsule and 1 from normal Tenon's capsule. There was a significant reduction of cellular proliferation in the cyclosporin exposed cultures (p<0.05). CONCLUSION: Cyclosporin 0.05 percent is effective to inhibit the proliferation of pterygia and normal Tenon's capsule fibroblasts. Further studies should be performed to define the role of cyclosporin in pterygium treatment.


Subject(s)
Humans , Cyclosporine/pharmacology , Fibroblasts/drug effects , In Vitro Techniques , Immunosuppressive Agents/pharmacology , Pterygium/pathology , Analysis of Variance , Case-Control Studies , Cells, Cultured , Cell Count/methods , Fibroblasts/cytology , Prospective Studies , Pterygium/surgery , Statistics, Nonparametric , Time Factors
3.
Arq Bras Oftalmol ; 69(6): 831-5, 2006.
Article in Portuguese | MEDLINE | ID: mdl-17273676

ABSTRACT

PURPOSE: To evaluate normal Tenon capsule fibroblasts and from pterygia in culture when exposed to cyclosporin 0.05%. METHODS: A prospective, randomized study was done, involving 20 patients with primary pterygium. Samples of normal and pterygium Tenon's capsule from the same individual were collected, cultured and exposed to cyclosporin 0.05%. RESULTS: Only 7 samples could be exposed to cyclosporin--6 from pterygial Tenon's capsule and 1 from normal Tenon's capsule. There was a significant reduction of cellular proliferation in the cyclosporin exposed cultures (p<0.05). CONCLUSION: Cyclosporin 0.05% is effective to inhibit the proliferation of pterygia and normal Tenon's capsule fibroblasts. Further studies should be performed to define the role of cyclosporin in pterygium treatment.


Subject(s)
Cyclosporine/pharmacology , Fibroblasts/drug effects , Immunosuppressive Agents/pharmacology , Pterygium/pathology , Analysis of Variance , Cell Count/methods , Cells, Cultured , Fibroblasts/cytology , Humans , Prospective Studies , Pterygium/surgery , Statistics, Nonparametric , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...